Eric Morand
Monash University
H-index: 76
Oceania-Australia
Top articles of Eric Morand
Local Ancestry at the Major Histocompatibility Complex Region is Not a Major Contributor to Disease Heterogeneity in a Multiethnic Lupus Cohort
Arthritis & Rheumatology
2024/1/30
Treatment of flares in lupus
2024/1/25
Autoimmune Rheumatic Diseases in Australian Aboriginal and Torres Strait Islander Peoples: What Do We Know?
2024/1/14
Predictors of organ damage in Systemic Lupus Erythematosus in the Asia Pacific region: A systematic review
2024/1/8
Eric Morand
H-Index: 40
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
2010/12/1
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis …
Annals of the Rheumatic Diseases
2024/4/3
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set
Seminars in arthritis and rheumatism
2024/4/1
TYK2: an emerging therapeutic target in rheumatic disease
2024/3/11
Eric Morand
H-Index: 40
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial
2024/3/1
Subhashis Banerjee
H-Index: 13
Eric Morand
H-Index: 40
P54 Screening for primary aldosteronism in hypertensive patients with systemic lupus erythematosus: are we doing it enough?
2024/3/1
LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
2024/3/1
Eric Morand
H-Index: 40
Hussein Al-Mossawi
H-Index: 11
O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI [4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 …
2024/3/1
Eric Morand
H-Index: 40
Subhashis Banerjee
H-Index: 13
Flare in Systemic Lupus Erythematosus: Lost in Translation?
2024/3/1
Preclinical evidence for the glucocorticoid-sparing potential of a dual toll-like receptor 7/8 inhibitor in autoimmune diseases
Journal of Pharmacology and Experimental Therapeutics
2024/3/1
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a …
Annals of the Rheumatic Diseases
2024/2/29
Smith-specific regulatory T cells halt the progression of lupus nephritis
Nature Communications
2024/2/6
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring
Rheumatology
2024/2/1
Compositions and methods for treating lupus
2023/8/31
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study
Arthritis & Rheumatology
2023/3
Co-Authors
